Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FertyBiotic Mujer
- Development stage
- Unknown
- Lead developer
- Fertypharm
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
FertyBiotic Mujer is a probiotic-based dietary supplement developed by Fertypharm S.L. specifically designed to support female fertility and reproductive health. It is formulated as a combination of nutritional components and live probiotics. The product contains myo-inositol, D-chiro-inositol (Caronositol®), folic acid (as the bioactive form Quatrefolic®), melatonin, selenium, and vitamin D3, alongside three specific probiotic strains: *Lacticaseibacillus rhamnosus*, *Lactobacillus crispatus*, and *Lactiplantibacillus plantarum*. These ingredients work synergistically to improve oocyte quality, enhance insulin sensitivity, provide antioxidant protection, and modulate the vaginal and endometrial microbiota to create an optimal environment for conception and pregnancy. It is administered orally as a powder dissolved in water, typically recommended for a three-month treatment period.
- Brand names
- FertyBiotic MujerFertyBiotic Woman
02
Targets
FOLR1 (FRα)MTNR1A (MT1)INSR (Insulin receptor)VDR (Vitamin D receptor)
Beyond the preview
Go deeper on FertyBiotic Mujer.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FertyBiotic Mujer.